



Original article

“Decoding hereditary breast cancer” benefits and questions from multigene panel testing

Chrystelle Colas ^{a, b}, Lisa Golmard ^{a, b}, Antoine de Pauw ^{a, b}, Sandrine M. Caputo ^{a, b},
Dominique Stoppa-Lyonnet ^{a, c, d, *}

^a Department of Genetics, Institut Curie, Paris, France

^b Paris Sciences Lettres Research University, Paris, France

^c Paris Descartes Sorbonne-Paris-Cité University, Paris, France

^d INSERM U830, Institut Curie Paris, Paris, France



ARTICLE INFO

Article history:

Received 8 October 2018

Received in revised form

3 January 2019

Accepted 7 January 2019

Available online 8 January 2019

Keywords:

Multigene panel

NGS

BRCA1

BRCA2

VUS

Analytical validity

Clinical validity

Clinical utility

ABSTRACT

Multigene panel testing for breast and ovarian cancer predisposition diagnosis is a useful tool as it makes possible to sequence a considerable number of genes in a large number of individuals. More than 200 different multigene panels in which the two major *BRCA1* and *BRCA2* breast cancer predisposing genes are included are proposed by public or commercial laboratories. We review the clinical validity and clinical utility of the 26 genes most often included in these panels. Because clinical validity and utility are not established for all genes and due to the heterogeneity of tumour risk levels, there is a substantial difficulty in the routine use of multigene panels if management guidelines and recommendations for testing relatives are not previously defined for each gene. Besides, the classification of variant of unknown significance (VUS) is a particular limitation and challenge. Efforts to classify VUSs and also to identify factors that modify cancer risks are now needed to produce personalised risk estimates. The complexity of information, the capacity to come back to patients when VUS are re-classified as pathogenic, and the expected large increase in the number of individuals to be tested especially when the aim of multigene panel testing is not only prevention but also treatment are challenging both for physicians and patients. Quality of tests, interpretation of results, information and accompaniment of patients must be at the heart of the guidelines of multigene panel testing.

© 2019 Published by Elsevier Ltd.

1. Introduction

Since its emergence around 2010, next generation sequencing (NGS) has been a breakthrough for medical genetic laboratories. As with whole exome and whole genome sequencing, NGS through multigene panels makes it possible to sequence a considerable number of genes in a large number of individuals. Multigene panel testing is useful for diagnosis of diseases with genetic heterogeneity and for disease risk estimates in predictive medicine.

In the field of cancer genetics and particularly breast cancer predisposition, panel testing has spread extensively and rapidly over academic and commercial laboratories. This is linked to the decision of the US Supreme Court in June 2013 to invalidate the patents that restricted *BRCA1/BRCA2* testing [1]. Indeed, these two

genes are the “core” of multigene panels exploring breast (and ovarian) cancer risks or more largely cancer risks. Invalidation of the patents resulted in decreased costs for genetic testing and more widespread availability to companies. In addition, the demand for breast cancer genetic testing worldwide has doubled since May 2013, when Angelina Jolie revealed that she is a carrier of a pathogenic *BRCA1* variant and that she had chosen to undergo prophylactic mastectomy [2]. Another reason for the rise in multigene breast cancer panels is the development of targeted therapies for cancers with homologous recombination (HR) deficiency, which makes identification of pathogenic variants in genes involved in HR, particularly *BRCA1* and *BRCA2*, a treatment prerequisite [3].

Multigene panel testing is time- and cost-efficient because it avoids sequential tests. It also provides extensive data, however, given the high number of genetic variants identified, transforming the data into information useful for each individual tested can prove difficult. We will review the main characteristics of the breast (and ovarian) cancer predisposing gene panels available, the

* Corresponding author. Department of Genetics, Institut Curie, Paris, France.
E-mail address: dominique.stoppa-lyonnet@curie.fr (D. Stoppa-Lyonnet).

required parameters of their analytical validity, clinical validity and clinical utility. The enormous capacity of gene sequencing has led “panel designers” to include genes whose clinical validity and utility are not established, thus producing “bulky” knowledge. What recommendations can be made for the use of the available breast (and ovarian) cancer multigene panels and for improving their clinical utility?

2. Available breast (and ovarian) cancer multigene panel testing

The latest release of the NCBI Genetic Test Registry lists more than 200 multigene panels including *BRCA1* and *BRCA2* that are proposed by academic or commercial laboratories [4]. Some but not all are specific to breast and ovarian cancer predisposing genes. The 26 genes most frequently included in breast (and ovarian) cancer panels are shown in Table 1. As previously stated, *BRCA1* and *BRCA2* are the core genes. The other genes are either associated with specific phenotypes and breast cancer risks (*TP53* and Li-Fraumeni syndrome; *CDH1* and lobular breast carcinoma and diffuse gastric carcinoma; *PTEN* and Hamartoma Tumour Syndrome; *STK11* and Peutz-Jeghers syndrome; *NF1* and neurofibromatosis type 1), or with ovarian cancer risks (*MLH1*, *MSH2/EPCAM*, *MSH6*, *PMS2*). They also include genes reportedly associated with a risk of breast cancer in case studies or case-control studies. Most are involved in DNA

repair, some of which are reportedly partners of *BRCA1* or *BRCA2* (*ATM*, *BARD1*, *BRIP1*, *GEN1*, *MCPH1*, *NBN*, *MRE11A*, *PALB2*, *RAD50*, *RAD51C*, *RAD51D*, *RECQL*, *RINT1*, *SLX4*, *XRCC2*), or in cell-cycle control or mitotic signal transduction (*CHEK1*, *CHEK2*, *PI3KCA*). The list is open and grows with each new study. The level of the associated breast/ovarian cancer risk differs depending on the genes: some genes, or rather their pathogenic variants, are associated with high risk, others with moderate risk and for others the reality of an increased risk has not yet been clearly established. The heterogeneity of the risk level of the sequenced genes and thus the diversity of management guidelines are a substantial difficulty in routine use of multigene panels.

3. Analytical validity

In analytical validity, we include the sensitivity and specificity of variant detection and their clinical interpretation or classification.

3.1. Sensitivity and specificity of variant detection

Lincoln et al. examined, in a series of 1105 individuals, the analytical concordance of 750 different variants of 29 genes using NGS versus Sanger sequencing, the gold standard of sequencing methods. There was 99.8% net report concordance [5]. Moreover, NGS technologies showed a higher sensitivity than Sanger

Table 1
Genes most frequently included in breast (and ovarian) cancer panels and their validity and clinical utility.

Gene	Clinical Validity/Risk Level		Clinical Utility			Main References
	Level of breast cancer risk	Level of ovarian cancer risk	Specific Guidelines			
			Breast	Ovary	Related syndrome	
<i>BRCA1</i>	High CLTR(80) 72% [51]	High CLTR(80) 44%	Yes ^b	Yes ^c		[51]
<i>BRCA2</i>	High CLTR(80) 69%	High CLTR(80) 17%	Yes ^b	Yes ^c		[51]
<i>PALB2</i>	High OR 6.56–9.47	Conflicted	Yes ^b	No		[52–57]
<i>TP53</i>	High RR 3.76; CLTR(70) 85%	Conflicted	Yes ^b	No	Li Fraumeni	[55,58]
<i>PTEN</i>	High CLTR(70): 67–85.2%	Low	Yes ^b	No	Cowden	[59–61]
<i>CDH1</i>	High RR 6.6–7.7; CLTR(80) 39–42%	Unknown	Yes ^b	No	HDGC	[62–64]
<i>STK11</i>	High, RR 15; CLTR(70) 77%	High RR 2; CLTR(70) 45%	Yes ^b	Yes ^d	Peutz Jeghers	[65,66]
<i>MLH1</i>	Conflicted	High CLTR(70): 20%	No	Yes ^d	Lynch	[55,67]
<i>MSH2/EPCAM</i>	Conflicted	High CLTR(70): 24%	No	Yes ^d	Lynch	[55,67]
<i>MSH6</i>	Conflicted	Conflicted	No	Yes ^d	Lynch	[55,67]
<i>PMS2</i>	Conflicted	Conflicted	No	Yes ^d	Lynch	[55,68]
<i>NF1</i>	Insufficient data	Insufficient data	Discussed	No	NF1	[69]
<i>RAD51C</i>	No evidence of association	High RR 5.2–6.31; CLTR(80): 9%	No	Yes		[70–74]
<i>RAD51D</i>	No evidence of association	High OR 6.3; CLTR(80) 13.56%	No	Yes		[72,75,76]
<i>ATM</i>	Low to moderate RR 1.5–3 ^a	No evidence of association	Discussed ^a	No		[57,77–79]
<i>CHEK2</i>	Low to moderate OR 1.58–3 ^a	Insufficient data	Discussed ^a	No		[77,80,81]
<i>BRIP1</i>	No evidence of association	Moderate RR 3.41; CLTR(80) 4–12.7%	No	Discussed		[77,82]
<i>BARD1</i>	Insufficient data	Insufficient data	No	No		[82,83]
<i>GEN1</i>	No evidence of association	No evidence of association	No	No		[84,85]
<i>RAD50</i>	Insufficient data	Insufficient data	No	No		[54,55]
<i>RINT1</i>	Conflicted	Insufficient data	No	No		[86,87]
<i>MRE11A</i>	Insufficient data	Insufficient data	No	No		[54]
<i>NBN</i>	Conflicted OR 1.4–2.66 ^a	No evidence of association	No	No		[55,82,88]
<i>XRCC2</i>	No excess risk Insufficient data	Insufficient data	No	No		[77,89]
<i>MCPH1</i>	Insufficient data	Insufficient data	No	No		[77]
<i>SLX4</i>	Insufficient data	Insufficient data	No	No		[77]

OR: odds ratio; RR relative risk; CLTR () cumulative lifetime risk (at age); HDGC hereditary diffuse gastric cancer; NF1 neurofibromatosis type I.

In the absence of specific guidelines, surveillance should be based on family history of breast and/or ovarian cancer, regardless of genetic result.

The clinical utility of genetic testing in relatives means that specific guidelines will be applied to carriers of the pathogenic variant and that surveillance will be stopped in non-carriers.

^a According to type of mutation.

^b Including breast MRI and prophylactic mastectomy.

^c Including prophylactic oophorectomy.

^d According to guidelines on related syndrome.

sequencing for mosaic variants, i.e. *de novo* variants that occur during embryonic development and are present in some but not all of an individual's cells. Conventional NGS can detect variants at low levels, up to 1%, while the limit of detection of Sanger sequencing is about 15–20% [6,7]. In breast cancer multigene panel testing, a low limit of detection is particularly important for *TP53* gene, which has an estimated *de novo* variant rate of at least 14% of *TP53* pathogenic variants identified, and one-fifth of these *de novo* variants are mosaics [8].

However, Sanger sequencing has better specificity than conventional NGS. Using Sanger sequencing, Mu et al. verified 7845 non-polymorphic variants identified through 20,000 hereditary-cancer panels spanning 47 genes. They found 98.7% concordance of the variants between NGS and Sanger sequencing, 1.3% were NGS false-positives. They were located in A/T- and G/C-rich regions, homopolymer stretches and pseudogenes. Simulation of a false-positive rate of zero by adjusting the variant-calling quality-score thresholds decreased the sensitivity from 100% to 97.8% and resulted in missed detection of 176 variants. These data illustrate the need for Sanger confirmation of NGS variants to maintain the highest possible sensitivity [9].

A great benefit of NGS is that it can most often detect both point variants and copy number variations (CNV) in one experiment. A recent survey examined worldwide genetic testing practices for *BRCA1/BRCA2*. Among the 86 laboratories that participated in the survey, 80 (93%) had moved towards NGS. Regarding detection of CNVs, 88% of laboratories in the US and 40% in Europe used NGS. It is expected that in the near future, NGS will also be adopted worldwide for CNV detection [10]. The same survey found that over half of laboratories confirmed variants (except neutral or likely neutral, see below) using another method, in most cases Sanger sequencing. The authors recommend that the results should mention such technical details as minimal read depths, analytical sensitivity and variant confirmation by an independent method. In order to assist clinical laboratories with analytical validation of NGS, the American College of Medical Genetics and Genomics (ACMG) has proposed comprehensive professional standards and guidelines concerning all steps in NGS, from DNA preparation and bioinformatic analysis to data reporting [11].

3.2. Clinical classification of variants

BRCA1 and *BRCA2*, along with other dominantly transmitted cancer predisposing genes, are associated with cancer risks through protein inactivating variants and therefore often through variants introducing a stop codon (nonsense, frameshift, splice defect) and more rarely missense variants. The classification of genetic variants in coding sequences or their intron-exon junctions as pathogenic or neutral is not a new challenge, nor is it NGS specific, however, because NGS is identifying an increasing number of variants, and the proportion of annotated variants is not increasing at the same rate, there is, according to Cutting, an ever-increasing “interpretive gap” that reopens and broadens the challenge [12].

Classification of variants is a particular limitation in *BRCA1/BRCA2* testing. More than 1000 pathogenic variants in each gene have been reported but the number of unclassified variants, variants of unknown significance (VUS), is double [13]. Plon et al. have proposed a classification of variants of cancer predisposing genes based on 5 levels: definitely pathogenic, likely pathogenic, unknown significance, likely not pathogenic and not pathogenic or of no clinical significance or neutral [14]. The classification of variants as pathogenic is of the utmost importance for the management of carriers. Guidelines for variant classification have also been proposed by the ACMG [15]. The classification of *BRCA1/BRCA2* and more recently *PALB2* genes is challenging and, in 2009, led to the

creation of the international consortium “Evidence-based Network for the Interpretation of Germline Mutant Alleles”, ENIGMA [16]. ENIGMA is the main actor in the BRCA Challenge, proof of concept of the Global Alliance for Genomics and Health, GA4GH, whose aim is to facilitate sharing of international data in medical genetics to improve the quality of genetic diagnoses [17,18]. Classification of each known *BRCA1/BRCA2* VUS based on pathogenicity relies on multiple approaches: higher frequency in cases than in controls, phylogenetic conservation of the nucleotide/amino-acid modified, Grantham score for missense variants, co-segregation of the VUS with the disease in multiplex families, abnormal transcripts, functional assays, etc. ENIGMA promotes sharing of efforts at classification by laboratories, clinical cancer geneticists and national variant database curators [19–22]. It should be noted that currently the classification of VUSs identified in non-Caucasian patients and in smaller ethnic groups is more difficult due to the lack of epidemiological data. Special effort should be made in these populations.

Overall, while it is of the utmost importance to classify VUSs, it is equally important to update the test results. In other words, laboratories need to have the ability to come back to patients and their physicians when a VUS has been classified. Indeed, it is expected that some VUSs, hopefully most of them, will be classified as pathogenic or neutral as more data are accrued. Conversely, some pathogenic variants have been “declassified” to non-pathogenic due to a residual functional protein derived from physiological alternative transcripts that were not previously taken into account [23]. Reporting of variants and their clinical classification has to be written clearly so that the numerous physicians who manage women at risk understand the results and use them appropriately. In a survey of 3672 women who had *BRCA1/BRCA2* testing in 2014–2015, Kurian et al. reported that 51% of women carrying a VUS underwent bilateral prophylactic mastectomy even in the absence of a severe family history [24]. In the Prospective Registry of Multiplex Testing (PROMPT), 26% of variants reported by at least two commercial laboratories were of conflicting interpretation [25]. In March 2016, the journalist Jeremy Lange reported in *The New York Times* the case of a woman whose doctors had conflicting information on her *BRCA1/BRCA2* test result. “The situation is ripe for overinterpretation and misinterpretation,” said a geneticist interviewed by Jeremy Lange. In summary, laboratories must collaborate with physicians in order to take into account patient clinical and familial data, contribute to and track the classification of variants and be able to pass on the updated variant classification to patients and their physicians. If these objectives are in the DNA of academic laboratories, they are not in that of commercial laboratories. It is however of the utmost importance to organise and sustain variant databases and to pursue all the efforts with all the actors of breast cancer genetic testing.

4. Clinical validity and clinical utility

The aim of predictive medicine is to limit the risk of an expected disease or to limit its impact on quality of life (including psychosocial outcomes) and to limit its mortality. We do not include here specific treatments such as PARP inhibitors in tumours with bi-allelic HR gene inactivation. The main aim of testing for breast (and ovarian) cancer genes is prevention in carriers of pathogenic variants and reassurance of non-carriers. If clinical validity refers to the accuracy with which a condition is identified and clinical utility to the benefits of management guidelines based on genetic testing, clinical validity and utility should be demonstrated before being put into clinical practice [26,27]. Because clinical validity and utility must be demonstrated for each gene in the panel, and because our knowledge of genes and tumour risk levels differ, the clinical use of breast (and ovarian) cancer multigene panel testing is challenging.

4.1. Clinical validity

Strande et al. for the NIH-funded Clinical Genome Resource (ClinGen) created a framework that provides evidence for the strength of the association between a gene and a disease or a disease risk through semi-quantitative classification: definitive, strong, moderate, limited, no reported evidence, or conflicting evidence [28]. The classification is based on genetics, i.e. cosegregation data, case and case-control studies, as well as experimental data, i.e. functional data, cell and animal models.

Some genes, such as *MEN1* and *CTNNB1*, included in some breast (and ovarian) multigene panels based on case reports seem to be “lost in translation”. Classification of clinical validity is a dynamic process, subject to new information. For example, until recently no studies reported an increased risk of breast cancer associated with *RAD51C* and *RAD51D* pathogenic variants, which were initially thought to be associated only with ovarian cancer. A first study performed in 65,000 women affected with breast cancer reported an increased risk of breast cancer with *RAD51D* [29]. A second and more recent study performed in 10,900 triple negative carcinoma (TN) cases, a subset of 140,000 breast cancer cases, confirmed the risk of breast cancer with *RAD51D* and identified an increased risk in carriers of *RAD51C* pathogenic variants, another paralogue of *RAD51* [30]. Due to the very low frequency of *RAD51C* and *RAD51D* carriers in the general population and the heterogeneity of breast cancer, with TN tumours representing 15% of breast cancers, the increased risk and therefore clinical validity were demonstrated with difficulty.

4.2. Clinical utility

Cancer risk estimates are the key point in defining management guidelines and thus clinical utility. Cancer risks are classified as high, moderate or low, each being associated with different management guidelines (Table 1). Low risk means less than two times as high as the risk in the general population, moderate risk 2 to 4 times as high, and high risk more than four times higher [27]. National guidelines on prophylactic mastectomy and breast MRI are well established and homogenous regarding carriers of high-risk genes (*BRCA1*, *BRCA2*, *PALB2*), while guidelines on moderate-risk genes (*ATM*, *CHEK2*) are not homogeneous. For the same gene, some recommend breast MRI when a test result is positive, while others take family history into account more so than the test result [31–34]. The heterogeneity of guidelines and practices regarding moderate-risk genes illustrates the extent to which clinical utility is not yet firmly established.

Another difficulty related to moderate-risk genes is the use of identified pathogenic variants for testing relatives. When a pathogenic *BRCA1* variant is identified in a woman, variant-targeted tests are offered to her relatives and when negative, relatives are reassured. When a pathogenic variant in a moderate-risk gene, such as *ATM*, is identified, especially in a woman with a severe family history, can a targeted test be offered to her relatives and, if negative, is it reassuring? Probably not, because we consider that the *ATM* variant does not “recap” the family history. The multigene panel test is generally presented as a single test, but it is actually a myriad of tests whose results are as numerous as the number of genes tested. Because the clinical utility of moderate-risk genes has not been firmly established and because the tests available to relatives are not unequivocal, the French Genetic and Cancer Group (GGC)-Unicancer chose not to include *ATM* and *CHEK2* in its breast (and ovarian) cancer multigene panel [31]. However, all multigene panels are welcome provided that the consequences of identifying a pathogenic variant for each gene have been anticipated in terms of follow-up and testing available to relatives.

Specific syndrome genes such as *TP53*, *CDH1*, *PTEN*, *STK11* and *NF1*, are included in most breast (and ovarian) cancer multigene panels. Specific guidelines have been published for carriers whose families have the syndrome. For example, in Li-Fraumeni syndrome, annual “head-to-toe” whole-body MRI is advised in *TP53* pathogenic variant carriers [35]. Does such stringent and stressful follow-up need to be conducted in *TP53* carriers identified through a multigene panel performed because, for example, two relatives developed breast cancer at age 50? A recent study by Rana et al. examined the phenotype of *TP53* carriers identified through multigene panels. Ages at diagnosis of breast cancer were older than reported in the classic Li-Fraumeni syndrome, suggesting that *TP53* pathogenic variants may have a broader phenotypic spectrum than previously reported [36]. The question is similar for *CDH1* carriers [37]. Should prophylactic gastrectomy before the age of 30 be recommended when no relative is affected with gastric carcinoma? Re-assessment of cancer risks by prospective studies is required in individuals whose genetic tests have been conducted outside stringent testing criteria, which is likely to be more frequent with increasing multigene panel use [38].

A similar question is raised regarding *BRCA1* and *BRCA2* carriers. Modifier factors, genetic or otherwise, have long been known to increase or decrease the risk of breast and ovarian cancer in carriers [39,40]. The aims of the international collaborative groups IBCCS (International *BRCA1/2* Carrier Cohort Study) and CIMBA (The Consortium of Investigators of Modifiers of *BRCA1/2*) are precisely to identify such modifier factors. Kuchenbaecker et al. have examined a polygenic risk score (PRS) based on the genotypes of 77 single nucleotide polymorphisms (SNP). The PRS modulates breast cancer risks at age 80 between 53% and 78% in *BRCA1* carriers and 35%–55% in *BRCA2* carriers [41] (and Cox et al. this issue). Similar studies are on-going for ovarian cancer risks. It is of particular importance to take into account modifier factors in personalised risk estimates when relatives are not affected with breast or ovarian cancers. The on-going BRIDGES project (Breast cancer Risk after Diagnostic GENE Sequencing) aims to combine, in addition to *BRCA1*, *BRCA2*, *ATM* and *CHEK2* variants, modifier factors including a PRS, [42]. Personalised risk estimates are urgently needed when some groups report that it is time to offer *BRCA1*, *BRCA2*, *RAD51C*, *RAD51D*, *BRIP1* and *PALB2* tests to all women over the age of 30 [43].

In summary, efforts to identify and combine factors that modify cancer risks linked to the different predisposing genes sequenced in multigene panels are needed to produce personalised risk estimates for women tested, as well as for her relatives, and thus to escape the bias of any testing criteria.

5. Perspectives and conclusion

Multigene panel testing is a promising tool that makes it possible to test a considerable number of genes in a large number of individuals. It is possible that in the future, when the coverage and minimal read depths are high and homogeneous, whole exome sequencing will be performed with a multigene panel reading. Whole exome and later whole genome sequencing associating genome spread SNPs and thus PRS, will be the “Swiss knife” of geneticists. Before this era, more widespread use of multigene panel is also likely to allow us to identify individuals with two predisposing genes (digenism), a situation probably more frequent than hitherto thought. Indeed, *BRCA2* carrier frequency in the Caucasian population may be as high as 1/192 and *ATM* carrier frequency 1/150 [44,45]. Currently, multigene panel testing is already a highly useful tool provided the results are not over-interpreted or misinterpreted. As genetic testing advances, research into the interpretation of VUSs, the accuracy of personalised risk estimates through the identification of risk-modifying factors must

continue. Studies are on-going through international efforts under the auspices of consortia such as ENIGMA, IBCCS, CIMBA and through data-sharing as in the BRCA Challenge. Special research efforts are required in individuals of non-occidental ethnic groups as few data are currently available. Diagnosis and research may be combined in the same multigene panel, however the genes sequenced for research should be defined and patients informed before testing. It is important to remember the bulk of our knowledge in this field was obtained thanks to patients and their families, and this situation has not changed. Information on the issues related to the tests and anticipation of possible results, including VUSs, are key points in genetic counselling.

The complexity of information, the capacity to come back to patients with updated results, such as when VUSs are re-classified as pathogenic, and the expected large increase in the number of individuals to be tested are challenging both for physicians and patients. Indeed, the treatment by PARP inhibitors of women affected with high grade ovarian cancer, TN breast cancer or metastatic breast cancer and whose tumours is inactivated for *BRCA1* or *BRCA2* is going to strongly increase the indications of breast (and ovarian) multigene panel testing and also to modify its process. For example, the recent study SOLO1 has demonstrated the interest of maintenance therapy by PARP inhibitor olaparib in newly diagnosed advanced high grade ovarian carcinoma in women whose tumour is inactivated for *BRCA1* or *BRCA2* through germline or somatic mutation events [46]. It is expected that in the near future multigene panel testing will be performed through tumour DNA with the double aim of treatment and prevention. It is important to keep in mind that *BRCA1/2* tumour testing (ovarian, breast and other locations) is a cancer predisposing test since 80% of pathogenic variants identified are germline [47]. Tumour DNA is the native DNA of the patient! Oncologists and surgeons need to work closely with clinical and molecular geneticists. It is paradoxical that at that time the Food and Drug Administration has authorised direct-to-consumer tests of three *BRCA1-2* pathogenic variants [48]. We can only speculate on what patients understand. ASCO and The European Breast Cancer Council (EBCC) recently issued guidelines for breast cancer predisposition testing. Quality of tests, information, interpretation of results and accompaniment of patients who have no choice when treatment is one of the objectives of genetic testing, are at the heart of the guidelines [49,50].

Acknowledgments

The authors would like to thank the physicians: Bruno Buecher, Emmanuelle Fourme, Sophie Frank, Marion Gauthier-Villars, Claire Saule, and the genetic counsellors: Ophélie Bertrand, Anne-Marie Birot, Anaïs Dupré and Marine Le Mentec who carefully read the manuscript and make useful comments. The authors thank also their colleagues (geneticists, biologists, oncologists, gynaecologists, surgeons, radiologists and psychologists), as well as the patients and their families who, through their questions, facilitated our thinking regarding this review.

Sandrine Caputo is supported by the French National Institute of Cancer for the curation of the *BRCA1/BRCA2/PALB2* variant database.

Astra Zeneca contributes financially to the COVAR study.

References

- [1] Assoc. For molecular pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). Justia Law n.d. <https://supreme.justia.com/cases/federal/us/569/576/> (accessed September 27, 2018).
- [2] Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. *Breast Canc Res BCR* 2014;16:442. <https://doi.org/10.1186/s13058-014-0442-6>.
- [3] Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? *Nat Rev Clin Oncol* 2018. <https://doi.org/10.1038/s41571-018-0055-6>.
- [4] Home - Genetic Testing Registry (GTR) - NCBI n.d. <https://www.ncbi.nlm.nih.gov/gate2.inist.fr/gtr/> (accessed 27 September 2018).
- [5] Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA, et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. *J Mol Diagn JMD* 2015;17:533–44. <https://doi.org/10.1016/j.jmoldx.2015.04.009>.
- [6] Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nat Rev Canc* 2017;17:223–38. <https://doi.org/10.1038/nrc.2017.7>.
- [7] Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. *J Mol Diagn JMD* 2010;12:425–32. <https://doi.org/10.2353/jmoldx.2010.090188>.
- [8] Renaux-Petel M, Charbonnier F, Théry J-C, Fermey P, Lienard G, Bou J, et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. *J Med Genet* 2018;55:173–80. <https://doi.org/10.1136/jmedgenet-2017-104976>.
- [9] Mu W, Lu H-M, Chen J, Li S, Elliott AM. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. *J Mol Diagn JMD* 2016;18:923–32. <https://doi.org/10.1016/j.jmoldx.2016.07.006>.
- [10] Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, Foulkes WD, et al. Clinical testing of *BRCA1* and *BRCA2*: a worldwide snapshot of technological practices. *NPJ Genom Med* 2018;3:7. <https://doi.org/10.1038/s41525-018-0046-7>.
- [11] Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. *Genet Med Off J Am Coll Med Genet* 2013;15:733–47. <https://doi.org/10.1038/gim.2013.92>.
- [12] Cutting GR. Annotating DNA variants is the next major goal for human genetics. *Am J Hum Genet* 2014;94:5–10. <https://doi.org/10.1016/j.ajhg.2013.12.008>.
- [13] Bérout C, Letovsky SI, Braastad CD, Caputo SM, Beaudoux O, Bignon YJ, et al. BRCA share: a collection of clinical BRCA gene variants. *Hum Mutat* 2016. <https://doi.org/10.1002/humu.23113>.
- [14] Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum Mutat* 2008;29:1282–91. <https://doi.org/10.1002/humu.20880>.
- [15] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and Genomics and the association for molecular pathology. *Genet Med Off J Am Coll Med Genet* 2015;17:405–24. <https://doi.org/10.1038/gim.2015.30>.
- [16] Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. ENIGMA - evidence-based Network for the Interpretation of Germline Mutant Alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in *BRCA1* and *BRCA2* genes. *Hum Mutat* 2012;33:2–7. <https://doi.org/10.1002/humu.21628>.
- [17] Global Alliance for Genomics and Health n.d. <https://www.ga4gh.org/> (accessed 27 September 2018).
- [18] Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou AC, et al. BRCA Challenge: BRCA Exchange as a global resource for variants in *BRCA1* and *BRCA2*. *PLoS Genet* Accepted.
- [19] Eccles DM, Mitchell G, Monteiro ANA, Schmutzler R, Couch FJ, Spurdle AB, et al. *BRCA1* and *BRCA2* genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. *Ann Oncol Off J Eur Soc Med Oncol* 2015;26:2057–65. <https://doi.org/10.1093/annonc/mdv278>.
- [20] Lincoln SE, Yang S, Cline MS, Kobayashi Y, Zhang C, Topper S, et al. Consistency of *BRCA1* and *BRCA2* variant classifications among clinical diagnostic laboratories. *JCO Precis Oncol* 2017;1.
- [21] Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Bérout C, Lidereau R. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-*BRCA1/BRCA2* databases. *Nucleic Acids Res* 2012;40:D992–1002. <https://doi.org/10.1093/nar/gkr1160>.
- [22] Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, et al. *BRCA1* R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. *J Med Genet* 2012;49. <https://doi.org/10.1136/jmedgenet-2012-101037>.
- [23] de la Hoya M, Soukarieh O, López-Perolio I, Vega A, Walker LC, van Ierland Y, et al. Combined genetic and splicing analysis of *BRCA1* c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. *Hum Mol Genet* 2016;25:2256–68. <https://doi.org/10.1093/hmg/ddw094>.
- [24] Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol* 2017;35:2232–9. <https://doi.org/10.1200/JCO.2016.71.6480>.
- [25] Balmaña J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective Registry of multiplex testing. *J Clin*

- Oncol Off J Am Soc Clin Oncol 2016;34:4071–8. <https://doi.org/10.1200/JCO.2016.68.4316>.
- [26] Burke W. Genetic tests: clinical validity and clinical utility. *Curr Protoc Hum Genet* Editor Board Jonathan Haines Al 2014;81:9. <https://doi.org/10.1002/0471142905.hg0915581>. 15.1-9.15.8.
- [27] Easton DF, Pharoah PDP, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med* 2015;372:2243–57. <https://doi.org/10.1056/NEJMs1501341>.
- [28] Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. *Am J Hum Genet* 2017;100:895–906. <https://doi.org/10.1016/j.ajhg.2017.04.015>.
- [29] Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol* 2017;3:1190–6. <https://doi.org/10.1001/jamaoncol.2017.0424>.
- [30] Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. *J Natl Canc Inst* 2018. <https://doi.org/10.1093/jnci/djy106>.
- [31] Moretta J, Berthet P, Bonadona V, Caron O, Cohen-Haguenuer O, Colas C, et al. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition]. *Bull Cancer (Paris)* 2018;105:907–17. <https://doi.org/10.1016/j.bulcan.2018.08.003>.
- [32] Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nat Rev Clin Oncol* 2016;13:581–8. <https://doi.org/10.1038/nrclinonc.2016.90>.
- [33] Taylor A, Brady AF, Frayling IM, Hanson H, Tischkowitz M, Turnbull C, et al. Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. *J Med Genet* 2018;55:372–7. <https://doi.org/10.1136/jmedgenet-2017-105188>.
- [34] Nielsen S, Nicolo AD, Eccles D, Romero IL, Domchek SM, Monteiro A, et al. Genetic testing and clinical management practices for variants in non-*BRCA1/2* breast (and/or ovarian) cancer susceptibility genes: an international survey by the enigma clinical working group. *J Clin Oncol* 2018. https://doi.org/10.1200/JCO.2018.36.15_suppl.1539.
- [35] Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. *JAMA Oncol* 2017;3:1634–9. <https://doi.org/10.1001/jamaoncol.2017.1968>.
- [36] Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, et al. Differences in TP53 mutation Carrier phenotypes emerge from panel-based testing. *J Natl Canc Inst* 2018;110:863–70. <https://doi.org/10.1093/jnci/djy001>.
- [37] Xie ZM, Li LS, Laquet C, Penault-Llorca F, Uhrhammer N, Xie XM, et al. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. *Cancer* 2011;117:3112–7. <https://doi.org/10.1002/cncr.25876>.
- [38] Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. *Breast Canc Res Treat* 2016;160:393–410. <https://doi.org/10.1007/s10549-016-4003-9>.
- [39] Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. *Genet Epidemiol* 2005;29:1–11. <https://doi.org/10.1002/gepi.20074>.
- [40] Chenévis-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, et al. An international initiative to identify genetic modifiers of cancer risk in *BRCA1* and *BRCA2* mutation carriers: the Consortium of Investigators of Modifiers of *BRCA1* and *BRCA2* (CIMBA). *Breast Canc Res BCR* 2007;9:104. <https://doi.org/10.1186/bcr1670>.
- [41] Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Ruos-Bloom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for *BRCA1* and *BRCA2* mutation carriers. *JAMA* 2017;317:2402–16. <https://doi.org/10.1001/jama.2017.7112>.
- [42] Bridges Research|Breast Cancer Risk after Diagnostic Gene Sequencing n.d. <https://bridges-research.eu/> (accessed 27 September, 2018).
- [43] Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, et al. Cost-effectiveness of population-based *BRCA1*, *BRCA2*, *RADS51C*, *RADS51D*, *BRIP1*, *PALB2* mutation testing in unselected general population women. *J Natl Canc Inst* 2018;110:714–25. <https://doi.org/10.1093/jnci/djx265>.
- [44] Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, et al. A risk prediction algorithm for ovarian cancer incorporating *BRCA1*, *BRCA2*, common alleles and other familial effects. *J Med Genet* 2015;52:465–75. <https://doi.org/10.1136/jmedgenet-2015-103077>.
- [45] Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, et al. Cancer risks and mortality in heterozygous *ATM* mutation carriers. *J Natl Canc Inst* 2005;97:813–22. <https://doi.org/10.1093/jnci/dji141>.
- [46] Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med* 2018. <https://doi.org/10.1056/NEJMoa1810858>.
- [47] Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. *Nat Commun* 2017;8:857. <https://doi.org/10.1038/s41467-017-00921-w>.
- [48] Commissioner O of the. Press Announcements - FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the *BRCA* breast cancer genes n.d. <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm599560.htm> (accessed 27 September 2018).
- [49] Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol Off J Am Soc Clin Oncol* 2015;33:3660–7. <https://doi.org/10.1200/JCO.2015.63.0996>.
- [50] Rutgers E, Balmana J, Beishon M, Benn K, Evans DG, Mansel R, et al. European Breast Cancer Council manifesto 2018: genetic risk prediction testing in breast cancer. *Eur J Canc Oxf Engl* 2019;106:45–53. <https://doi.org/10.1016/j.ejca.2018.09.019>. 1990.
- [51] Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Ruos-Bloom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for *BRCA1* and *BRCA2* mutation carriers. *JAMA* 2017;317:2402–16. <https://doi.org/10.1001/jama.2017.7112>.
- [52] Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-cancer risk in families with mutations in *PALB2*. *N Engl J Med* 2014;371:497–506. <https://doi.org/10.1056/NEJMoa1400382>.
- [53] Thompson ER, Rowley SM, Li N, McInerney S, Devereux L, Wong-Brown MW, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. *J Clin Oncol Off J Am Soc Clin Oncol* 2016;34:1455–9. <https://doi.org/10.1200/JCO.2015.63.7454>.
- [54] Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol* 2017;3:1190–6. <https://doi.org/10.1001/jamaoncol.2017.0424>.
- [55] Lu H-M, Li S, Black MH, Lee S, Hoiness R, Wu S, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. *JAMA Oncol* 2018. <https://doi.org/10.1001/jamaoncol.2018.2956>.
- [56] Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PDP, Sinilnikova OM, Beesley J, et al. Genetic variation at 9p22.2 and ovarian cancer risk for *BRCA1* and *BRCA2* mutation carriers. *J Natl Canc Inst* 2011;103:105–16. <https://doi.org/10.1093/jnci/djq494>.
- [57] Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, et al. *PALB2*, *CHEK2* and *ATM* rare variants and cancer risk: data from COGS. *J Med Genet* 2016;53:800–11. <https://doi.org/10.1136/jmedgenet-2016-103839>.
- [58] Mai PL, Best AF, Peters JA, DeCastro R, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation-carriers in the NCI LFS cohort. *Cancer* 2016;122:3673–81. <https://doi.org/10.1002/cncr.30248>.
- [59] Tan M-H, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline *PTEN* mutations. *Clin Cancer Res Off J Am Assoc Canc Res* 2012;18:400–7. <https://doi.org/10.1158/1078-0432.CCR-11-2283>.
- [60] Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Colas C, Möller P, Hes FJ, et al. Is colorectal surveillance indicated in patients with *PTEN* mutations? *Colorectal Dis Off J Assoc Coloproctol G B Irel* 2012;14:e562–566. <https://doi.org/10.1111/j.1463-1318.2012.03121.x>.
- [61] Daniels MS, Rich T, Weissman S, Pilarski R. Lifetime cancer risks of *PTEN* mutation carriers—letter. *Clin Cancer Res Off J Am Assoc Canc Res* 2012;18:4213. <https://doi.org/10.1158/1078-0432.CCR-12-0577>. author reply 4214.
- [62] Pharoah PDP, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in *CDH1* (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 2001;121:1348–53. <https://doi.org/10.1053/gast.2001.29611>.
- [63] Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, et al. Founder and recurrent *CDH1* mutations in families with hereditary diffuse gastric cancer. *JAMA* 2007;297:2360–72. <https://doi.org/10.1001/jama.297.21.2360>.
- [64] Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: *CDH1* mutations and beyond. *JAMA Oncol* 2015;1:23–32. <https://doi.org/10.1001/jamaoncol.2014.168>.
- [65] Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. *Gastroenterology* 2000;119:1447–53. <https://doi.org/10.1053/gast.2000.20228>.
- [66] Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, et al. Frequency and spectrum of cancers in the Peutz–Jeghers syndrome. *Clin Cancer Res Off J Am Assoc Canc Res* 2006;12:3209–15. <https://doi.org/10.1158/1078-0432.CCR-06-0083>.
- [67] Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in *MLH1*, *MSH2*, and *MSH6* genes in Lynch syndrome. *JAMA* 2011;305:2304–10. <https://doi.org/10.1001/jama.2011.743>.
- [68] Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, et al. Cancer risks for *PMS2*-associated lynch syndrome. *J Clin Oncol Off J Am Soc Clin Oncol* 2018. <https://doi.org/10.1200/JCO.2018.78.4777>. JCO2018784777.
- [69] Howell SJ, Hockenhuil K, Salih Z, Evans DG. Increased risk of breast cancer in neurofibromatosis type 1: current insights. *Breast Canc Dove Med Press* 2017;9:531–6. <https://doi.org/10.2147/BCTT.S11397>.
- [70] Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, et al. *RADS51C* is a susceptibility gene for ovarian cancer. *Hum Mol Genet* 2011;20:3278–88. <https://doi.org/10.1093/hmg/ddr229>.
- [71] Loveday C, Turnbull C, Ruark E, Nicol RMM, Ramsay E, Hughes D, et al. Germline *RADS51C* mutations confer susceptibility to ovarian cancer. *Nat Genet* 2012;44:475–6. <https://doi.org/10.1038/ng.2224>. author reply 476.

- [72] Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. *J Clin Oncol Off J Am Soc Clin Oncol* 2015;33:2901–7. <https://doi.org/10.1200/JCO.2015.61.2408>.
- [73] Sopik V, Akbari MR, Narod SA. Genetic testing for RAD51C mutations: in the clinic and community. *Clin Genet* 2015;88:303–12. <https://doi.org/10.1111/cge.12548>.
- [74] Li J, Meeks H, Feng B-J, Healey S, Thorne H, Makunin I, et al. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. *J Med Genet* 2016;53:34–42. <https://doi.org/10.1136/jmedgenet-2015-103452>.
- [75] Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nat Genet* 2011;43:879–82. <https://doi.org/10.1038/ng.893>.
- [76] Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, et al. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. *J Med Genet* 2012;49:429–32. <https://doi.org/10.1136/jmedgenet-2012-100852>.
- [77] Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nat Rev Clin Oncol* 2016;13:581–8. <https://doi.org/10.1038/nrclinonc.2016.90>.
- [78] Cavaciuti E, Laugé A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D, et al. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. *Genes Chromosomes Cancer* 2005;42:1–9. <https://doi.org/10.1002/gcc.20101>.
- [79] Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, et al. Rare variants in the ATM gene and risk of breast cancer. *Breast Canc Res BC* 2011;13:R73. <https://doi.org/10.1186/bcr2919>.
- [80] Weischer M, Nordestgaard BG, Pharoah P, Bolla MK, Nevanlinna H, Van't Veer LJ, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol* 2012;30:4308–16. <https://doi.org/10.1200/JCO.2012.42.7336>.
- [81] Han F, Guo C, Liu L. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. *DNA Cell Biol* 2013;32:329–35. <https://doi.org/10.1089/dna.2013.1970>.
- [82] Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. *J Natl Canc Inst* 2015;107. <https://doi.org/10.1093/jnci/djv214>.
- [83] Slavin TP, Maxwell KN, Lilyquist J, Vijai J, Neuhausen SL, Hart SN, et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. *NPJ Breast Canc* 2017;3:22. <https://doi.org/10.1038/s41523-017-0024-8>.
- [84] Kuligina ES, Sokolenko AP, Mitiushkina NV, Aбыsheva SN, Preobrazhenskaya EV, Gorodnova TV, et al. Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. *Fam Cancer* 2013;12:129–32. <https://doi.org/10.1007/s10689-012-9575-x>.
- [85] Turnbull C, Hines S, Renwick A, Hughes D, Pernet D, Elliott A, et al. Mutation and association analysis of GEN1 in breast cancer susceptibility. *Breast Canc Res Treat* 2010;124:283–8. <https://doi.org/10.1007/s10549-010-0949-1>.
- [86] Park DJ, Tao K, Le Calvez-Kelm F, Nguyen-Dumont T, Robinot N, Hammet F, et al. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. *Cancer Discov* 2014;4:804–15. <https://doi.org/10.1158/2159-8290.CD-14-0212>.
- [87] Li N, Thompson ER, Rowley SM, McInerney S, Devereux L, Goode D, et al. Reevaluation of RINT1 as a breast cancer predisposition gene. *Breast Canc Res Treat* 2016;159:385–92. <https://doi.org/10.1007/s10549-016-3944-3>.
- [88] Gao P, Ma N, Li M, Tian Q-B, Liu D-W. Functional variants in NBS1 and cancer risk: evidence from a meta-analysis of 60 publications with 111 individual studies. *Mutagenesis* 2013;28:683–97. <https://doi.org/10.1093/mutage/get048>.
- [89] Decker B, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK, et al. Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. *J Med Genet* 2017;54:732–41. <https://doi.org/10.1136/jmedgenet-2017-104588>.